hyperparathyroidism
HYPERPARATHYROIDISM

Hyperparathyroidism is a condition wherein there is an excessive production of parathyroid hormone (PTH).

Primary hyperparathyroidism is the most common endocrine disorder and an important cause of hypercalcemia in ambulatory patients.

Classic signs and symptoms include bone disease, kidney stones and hypercalcinosis.

Primary goal of pharmacological therapy is to normalize calcium levels.

 

Hyperparathyroidism Management

Prevention

  • For patients taking thiazide diuretics, discontinue for 2 weeks before serum calcium level measurement is repeated
  • Recommended for patients who do not undergo sugery
    • Avoid hypercalcemia-aggravating factors
    • Encourage physical activity to minimize bone resorption
    • Adequate hydration is encouraged to minimize nephrolithiasis risk
    • Moderate calcium intake (1000 mg/day) should be maintained
    • Moderate calcium restriction (<800 mg/day) is warranted in patients w/ high serum calcitriol concentration
    • Maintain moderate vitamin D intake (400-800 IU 24 hrly) to maintain 25-(OH)-D level of at least 20 or 30 ng/mL (50 or 75 mmol/L)

Follow Up

  • Annual serum calcium, creatinine & eGFR assessment
  • 3-site dual energy x-ray absorptiometry scan should be done every 1-2 years
  • Bone mineral density assessment every 1-2 years in cases of chronic disorder
  • Radiograph or vertebral fracture assessment done in patients suspected w/ vertebral fracture (ie back pain, height loss)
  • 24-hour biochemical stone profile done once indicated in suspected cases of renal nephrolithiasis or nephrocalcinosis
  • Abdominal imaging w/ radiography, CT or ultrasound is recommended in patients suspected w/ renal nephrolithiasis or nephrocalcinosis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
28 Apr 2020
Women who skip breakfast before and during early pregnancy have a higher risk of developing gestational diabetes mellitus (GDM) than those who have the essential meal daily, suggests a study.
Pearl Toh, 23 Sep 2020
Adding dapagliflozin to standard of care (SOC) significantly reduces the risk of worsening kidney function, death due to kidney or cardiovascular (CV) disease, and all-cause mortality compared with SOC alone in patients with chronic kidney disease (CKD), regardless of whether they have type 2 diabetes (T2D), reveals the DAPA-CKD* trial — showing dapagliflozin charting new territories from diabetes to the renal realm.
Roshini Claire Anthony, 23 Sep 2020

In patients with chronic heart failure with reduced ejection fraction (HFrEF), empagliflozin reduced the risk of cardiovascular (CV) death or heart failure hospitalization (HHF) and decline in estimated glomerular filtration rate (eGFR), results of the EMPEROR-Reduced* trial showed.